MedTrace Logo

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

NCT05382156 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 206

Last updated 2025-11-20

No results posted yet for this study

Summary

This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome

Conditions

  • Endogenous Cushing's Syndrome

Interventions

DRUG

Osilodrostat

oral administration of Osilodrostat tablets at different doses according to patient's need

Sponsors & Collaborators

  • RECORDATI GROUP

    lead INDUSTRY

Principal Investigators

  • Mario Maldonado, MD · Recordati AG - Head of Clinical Development

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-13
Primary Completion
2027-06-30
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Italy
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05382156 on ClinicalTrials.gov